Drug Trial Radar · NCT03281538
Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Last checked: Nov 19, 2026Latest source record: Oct 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
288
Actual
Start
Aug 14, 2017
Primary completion
Feb 11, 2020
Study completion Feb 11, 2020
Sponsor
- Lead sponsor
- Cara Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 13, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks.
Conditions
- Uremic Pruritus
Interventions
CR845Drug
IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With AEsTime frame: Up to 52 weeks
Locations
27 sites in 2 countries. Site status is shown where the registry gives one.
Cara Therapeutics Study Site
Chula Vista, California
Cara Therapeutics Study Site
El Centro, California
Cara Therapeutics Study Site
Long Beach, California
Cara Therapeutics Study Site
Northridge, California
Cara Therapeutics Study Site
Denver, Colorado
Cara Therapeutics Study Site
Hollywood, Florida
Cara Therapeutics Study Site
Tampa, Florida
Cara Therapeutics Study Site
Winter Park, Florida
Cara Therapeutics Study Site
Albany, Georgia
Cara Therapeutics Study Site
Augusta, Georgia
Cara Therapeutics Study Site
Meridian, Idaho
Cara Therapeutics Study Site
Springfield, Massachusetts
Cara Therapeutics Study Site
Roseville, Michigan
Cara Therapeutics Study Site
Kansas City, Missouri
Cara Therapeutics Study Site
Albuquerque, New Mexico
Cara Therapeutics Study Site
Gallup, New Mexico
Cara Therapeutics Study Site
Mineola, New York
Cara Therapeutics Study Site
Ridgewood, New York
Cara Therapeutics Study Site
Bethlehem, Pennsylvania
Cara Therapeutics Study Site
Knoxville, Tennessee
Cara Therapeutics Study Site
El Paso, Texas
Cara Therapeutics Study Site
San Antonio, Texas
Cara Therapeutics Study Site
San Antonio, Texas
Cara Therapeutics Study Site
San Antonio, Texas
Cara Therapeutics Study Site
St. George, Utah
Cara Therapeutics Study Site
Wauwatosa, Wisconsin
Cara Therapeutics Study Site
San Juan, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.